text_1: Zafgen reports promising results from weight-loss drug study
text_2: This article presents business developments related to Zafgen’s beloranib drug in a clear and accessible manner. But there was room for improvement in several areas, including sourcing. The only sources interviewed have links to Zafgen and were involved with the study being reported on. The story also could have done a better job reporting on the quantitative results of the study. For example, it never defines what it means by “significant” when discussing the weight loss achieved by study participants. Prader-Willi syndrome is a rare but life-threatening cause of obesity for which there is no current treatment. The drug candidate beloranib, if successful, would then be the first treatment for this patient population.